← Leaderboards
Qiang Wen
Northwestern University At Chicago
$670,316
Attributed
$670,316
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $148.5K · FY2016–20$200K$150K$100K$50K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$670,316 · 1
By mechanism
R50$670,316 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Cara J Gottardi$10,515,510
- Seema Khan$8,985,480
- Vasil V Galat$333,115
- Maureen McNulty$97,195
- Barbara M Buttin$243,158
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadMalignant - DescriptorLaboratoriesAreaAnticancer ResearchAcute Megakaryocytic LeukemiasAntitumor AgentAnimal ModelCell CycleCell DivisionCohesinDesignDrug DevelopmentFundingHematologic NeoplasmsHematologyHematopoietic NeoplasmsInhibitor/AntagonistInternationalInvestigationIn Vitro ActivityIn VivoKinase InhibitorMalignant Neoplasms
Grant awards (5)
Development of novel therapies for megakaryocytic malignancies$148,545
R50 · FY2020 · CA · contact PI
Development of novel therapies for megakaryocytic malignancies$130,753
R50 · FY2019 · CA · contact PI
Development of novel therapies for megakaryocytic malignancies$130,753
R50 · FY2018 · CA · contact PI
Development of novel therapies for megakaryocytic malignancies$130,753
R50 · FY2017 · CA · contact PI
Development of novel therapies for megakaryocytic malignancies$129,512
R50 · FY2016 · CA · contact PI